J&J reports five-year survival data
Johnson & Johnson said five-year overall survival rate was 69.2% and median progression-free survival was 60.5 months.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Johnson & Johnson said five-year overall survival rate was 69.2% and median progression-free survival was 60.5 months.
BeiGene (NASDAQ: ONC ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary BeiGene reported strong Q2 2026 financial results with $1.7 billion in t